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A B S T R A C T
Background
Most people who receive a kidney transplant die from either cardiovascular disease or cancer before their transplant fails. The most
common reason for someone with a kidney transplant to lose the function of their transplanted kidney necessitating return to dialysis
is chronic kidney transplant scarring. Immunosuppressant drugs have side eGects that increase risks of cardiovascular disease, cancer
and chronic kidney transplant scarring. Belatacept may provide suGicient immunosuppression while avoiding unwanted side eGects of
other immunosuppressant drugs. However, high rates of post-transplant lymphoproliferative disease (PTLD) have been reported when
belatacept is used in particular kidney transplant recipients at high dosage.
Objectives
1) Compare the relative eGicacy of belatacept versus any other primary immunosuppression regimen for preventing acute rejection,
maintaining kidney transplant function, and preventing death. 2) Compare the incidence of several adverse events: PTLD; other
malignancies; chronic transplant kidney scarring (IF/TA); infections; change in blood pressure, lipid and blood sugar control. 3) Assess
any variation in eGects by study, intervention and recipient characteristics, including: diGerences in pre-transplant Epstein Barr virus
serostatus; belatacept dosage; and donor-category (living, standard criteria deceased, or extended criteria deceased).
Search methods
We searched the Cochrane Renal Group's Specialised Register to 1 September 2014 through contact with the Trials' Search Co-ordinator
using search terms relevant to this review.
Selection criteria
Randomised controlled trials (RCT) that compared belatacept versus any other immunosuppression regimen in kidney transplant
recipients were eligible for inclusion.
Data collection and analysis
Two authors independently extracted data for study quality and transplant outcomes and synthesized results using random eGects meta-
analysis, expressed as risk ratios (RR) and mean diGerences (MD), both with 95% confidence intervals (CI).   Subgroup analyses and
univariate meta-regression were used to investigate potential heterogeneity.
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Main results
We included five studies that compared belatacept and calcineurin inhibitors (CNI) that reported data from a total of 1535 kidney transplant
recipients. Of the five studies, three (478 participants) compared belatacept and cyclosporin and two (43 recipients) compared belatacept
and tacrolimus.  Co-interventions included basiliximab (4 studies, 1434 recipients); anti-thymocyte globulin (1 study, 89 recipients);
alemtuzumab (1 study, 12 recipients); mycophenolate mofetil (MMF, 5 studies, 1509 recipients); sirolimus (1 study, 26 recipients) and
prednisone (5 studies, 1535 recipients).
Up to three years following transplant, belatacept and CNI-treated recipients were at similar risk of dying (4 studies, 1516 recipients: RR
0.75, 95% CI 0.39 to 1.44), losing their kidney transplant and returning to dialysis (4 studies, 1516 recipients: RR 0.91, 95% CI 0.61 to 1.38),
and having an episode of acute rejection (4 studies, 1516 recipients: RR 1.56, 95% CI 0.85 to 2.86). Belatacept-treated kidney transplant
recipients were 28% less likely to have chronic kidney scarring (3 studies, 1360 recipients: RR 0.72, 95% CI 0.55 to 0.94) and also had better
graM function (measured glomerular filtration rate (GFR) (3 studies 1083 recipients): 10.89 mL/min/1.73 m2, 95% CI 4.01 to 17.77; estimated
GFR (4 studies, 1083 recipients): MD 9.96 mL/min/1.73 m2, 95% CI 3.28 to 16.64) than CNI-treated recipients. Blood pressure was lower
(systolic (2 studies, 658 recipients): MD -7.51 mm Hg, 95% CI -10.57 to -4.46; diastolic (2 studies, 658 recipients): MD -3.07 mm Hg, 95% CI
-4.83 to -1.31, lipid profile was better (non-HDL (3 studies 1101 recipients): MD -12.25 mg/dL, 95% CI -17.93 to -6.57; triglycerides (3 studies
1101 recipients): MD -24.09 mg/dL, 95% CI -44.55 to -3.64), and incidence of new-onset diabetes aMer transplant was reduced by 39% (4
studies (1049 recipients): RR 0.61, 95% CI 0.40 to 0.93) among belatacept-treated versus CNI-treated recipients.
Risk of PTLD was similar in belatacept and CNI-treated recipients (4 studies, 1516 recipients: RR 2.79, 95% CI 0.61 to 12.66) and was no
diGerent among recipients who received diGerent belatacept dosages (high versus low dosage: ratio of risk ratios (RRR) 1.06, 95% CI 0.11
to 9.80, test of diGerence = 0.96) or among those who were Epstein Barr virus seronegative compared with those who were seropositive
before their kidney transplant (seronegative versus seropositive; RRR 1.49, 95% CI 0.15 to 14.76, test for diGerence = 0.73).
The belatacept dose used (high versus low), type of donor kidney the recipient received (extended versus standard criteria) and whether
the kidney transplant recipient received tacrolimus or cyclosporin made no diGerence to kidney transplant survival, incidence of acute
rejection or estimated GFR. Selective outcome reporting meant that data for some key subgroup comparisons were sparse and that
estimates of the eGect of treatment in these groups of recipients remain imprecise.
Authors' conclusions
There is no evidence of any diGerence in the eGectiveness of belatacept and CNI in preventing acute rejection, graM loss and death, but
treatment with belatacept is associated with less chronic kidney scarring and better kidney transplant function. Treatment with belatacept
is also associated with better blood pressure and lipid profile and a lower incidence of diabetes versus treatment with a CNI. Important
side eGects (particularly PTLD) remain poorly reported and so the relative benefits and harms of using belatacept remain unclear. Whether
short-term advantages of treatment with belatacept are maintained over the medium- to long-term or translate into better cardiovascular
outcomes or longer kidney transplant survival with function remains unclear. Longer-term, fully reported and published studies comparing
belatacept versus tacrolimus are needed to help clinicians decide which patients might benefit most from using belatacept.
P L A I N   L A N G U A G E   S U M M A R Y
Belatacept for kidney transplant recipients
Kidney transplants can improve the quality and length of life for patients with end-stage kidney disease (ESKD) compared with chronic
dialysis. To prevent a kidney transplant from being rejected by the body, immune-system suppressing drugs (most commonly a calcineurin
inhibitors (CNI)) are used. CNI are associated with high blood pressure, high lipid levels, an increased risk of developing diabetes, and
chronic scarring of the kidney transplant. Chronic kidney scarring is the main reason that kidney transplants lose function in people who do
not die before their kidney transplant fails. Belatacept might be an alternative immune-system suppressing drug which prevents rejection
but which also causes fewer side-eGects than CNI.
We included five studies that compared belatacept and calcineurin inhibitors (CNI) and enrolled 1535 kidney transplant recipients. We
found that belatacept was no diGerent to a CNI at being able to prevent acute rejection and at keeping a transplanted kidney working.
Recipients who received belatacept had lower blood pressure, less diabetes and better kidney transplant function than recipients who
received a CNI. The chance of dying aMer a kidney transplant was similar in recipients treated with belatacept and CNI.
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Summary of findings for the main comparison.
Belatacept versus calcineurin inhibitors (CNI) for kidney transplant recipients
Patient or population: Kidney transplant recipients
Settings: multinational
Intervention: Belatacept (any dosage)
Comparison: CNI
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
CNI Belatacept
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Death 57.5 per 1000 43.0 per 1000 (22.4 to 82.8) 0.75 (0.39 to 1.44) 1516 (4) High quality  
Loss of kidney trans-
plant
59.5 per 1000 54.1 per 1000 (36.3 to 82.1) 0.91 (0.61 to 1.38) 1516 (4) High quality  
Acute rejection 164.7 per 1000 257.0 per 1000 (140.0 to 471.0) 1.56 (0.85 to 2.86) 1516 (4) High quality  
Chronic kidney scar-
ring
413.3 per 1000 297.4 per 1000 (227.2 to 388.2) 0.72 (0.55 to 0.94) 1350 (3) High quality  
Malignancy 37.7 per 1000 37.7 per 1000 (21.9 to 64.8) 1.00 (0.58 to 1.72) 1516 (4) Moderate quality  
PTLD 10.9 per 1000 30.4 per 1000 (6.6 to 138.0) 2.79 (0.61 to 12.66) 1516 (4) Moderate quality Very low qual-
ity for Epstein
Barr virus and
belatacept
dosage sub-
groups
New onset diabetes 67.2 per 1000 50.0 per 1000 (26.9 to 62.5) 0.61 (0.40 to 0.93) 1049 (4) Moderate quality  
Delayed graM func-
tion
321.0 per 1000 298.5 per 1000 (253.6 to 349.9) 0.93 (0.79 to 1.09) 1209 (2) High quality  
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Presence of donor
specific antibodies
18.5 per 1000 2.6 per 1000 (0.2 to 24.2) 0.14 (0.01 to 1.31) 1209 (2) Moderate quality  
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio; MD: Mean Difference.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
PTLD - post-transplant lymphoproliferative disorder
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B A C K G R O U N D
Description of the condition
Kidney transplantation can oGer most people with end-stage
kidney disease (ESKD) improved quality and length of life
compared with remaining on chronic dialysis (Wong 2012). Short-
term survival of a kidney transplant has improved significantly over
the last 20 years since the introduction of cyclosporin, but medium-
to long-term kidney and recipient outcomes have not. One-year
kidney transplant survival in the United States is 95% for recipients
of living and 89% for recipients of deceased donor kidneys whereas
five-year kidney transplant survival falls to 80% for recipients of
living and 67% for recipients of deceased donor kidneys (SRTR
2010). This trend is also evident in Australia and New Zealand where
one-year first kidney transplant survival for living and deceased
donor kidneys is 97% and 92%, falling to 90% and 82% by five years
(ANZDATA 2012).
Most people who receive a kidney transplant die with a transplant
that is still working. Cardiovascular disease and cancer are the
biggest causes of death among people with a kidney transplant.
Calcineurin inhibitors (CNI) cause high blood pressure, diabetes
and high blood lipid levels, as well as impaired immune system
detection of cancer cells and antiviral immune activity (Buell
2005; Meier-Kriesche 2004; Nankivell 2003; Vanrenterghem 2008;
Vincenti 2007). Of those kidney transplant recipients who do not
die with their transplant still working, chronic kidney transplant
scarring is the biggest cause of losing kidney function (requiring
recommencement of dialysis). Chronic kidney transplant scarring
(also known as interstitial fibrosis/tubular atrophy or IF/TA) can
be caused by toxicity from CNI, but also by ischaemia-reperfusion
injury at around the time of the transplant and immune injury from
acute or chronic rejection aMer the transplant (Nankivell 2003).
Avoiding cardiovascular disease, cancer and chronic transplant
kidney scarring may improve medium- and long-term recipient and
kidney transplant outcomes.
Description of the intervention
Belatacept – a biologic immunosuppressive agent – is an inhibitor
of T-cell co-stimulation, was approved by the United States Food
and Drug Administration (FDA) in June 2011 for use in adult
recipients of kidney transplants. It was approved on the basis
of results from three randomised controlled trials (RCTs) which
enrolled 1425 recipients comparing belatacept to cyclosporin in
a regimen with concomitant use of MMF and steroids. In all
three studies, belatacept was demonstrated to be non-inferior to
cyclosporin in preventing acute rejection in kidney transplants
(BENEFIT Study 2008; BENEFIT-EXT 2009; Vincenti 2007).
How the intervention might work
A direct antagonist of the ligands CD80 and CD86 present on
antigen-presenting cells, belatacept prevents activation of the
T-cell CD28 receptor. This specificity is designed to eliminate
the non-immunological activity associated with conventional
immunosuppressive agents while providing potent inhibition of
T-cell activation and proliferation required for preventing acute
rejection (Sayegh 1998).
Why it is important to do this review
CNI avoidance, minimisation and substitution strategies have
all been tried in clinical studies in the past (Ekberg 2009;
Flechner 2011; Watson 2005). None of these regimens found
the optimal balance between suGicient immunosuppression to
avoid kidney transplant rejection and the avoidance of unwanted
side eGects. FDA approval for belatacept use is limited to a low
dose regimen in Epstein Barr seropositive adult kidney transplant
recipients because early clinical studies reported an increased
incidence of PTLD when belatacept was used in Epstein Barr
seronegative recipients or in a high dosage regimen (Vincenti 2005).
Before belatacept can be used widely, clinicians require a more
comprehensive understanding of its benefits and harms to ensure
that it is used appropriately and safely for specific kidney transplant
recipients (Webster 2009).
This review aimed to synthesise data from RCTs that compared
belatacept with other primary maintenance immunosuppression
regimens.
O B J E C T I V E S
1. Compare the relative eGicacy of belatacept versus any
other primary immunosuppression regimen for preventing
acute rejection, maintaining kidney transplant function, and
preventing death.
2. Compare the incidence of several adverse events: PTLD; other
malignancies; chronic transplant kidney scarring; infections;
change in blood pressure, lipid and blood sugar control.
3. Assess any variation in eGects by study, intervention and
recipient characteristics, including: diGerences in pre-transplant
Epstein Barr virus serostatus; belatacept dosage; and donor-
category (living, standard criteria deceased, or extended criteria
deceased).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCT and quasi-RCT, whether published or available
only in abstract form.
Types of participants
We included all adults and children receiving a kidney transplant
from a living or deceased donor (standard or extended criteria), in
whom belatacept was tested versus any other immunosuppressive
agent in a primary induction and maintenance regimen.
Kidney transplant recipients in whom belatacept was tested
against any other immunosuppressive agent in a secondary
immunosuppression regimen were excluded, i.e. when treatment
was changed due to acute rejection or chronic kidney scarring or
calcineurin-inhibitor (CNI) toxicity. We also excluded recipients who
received another solid organ in addition to a kidney transplant (e.g.
kidney and pancreas).
Types of interventions
1. Belatacept given in combination with any other
immunosuppressive co-intervention in which control recipients
received no belatacept, placebo, or another agent that the
belatacept arm did not receive
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2. Belatacept given in combination with any other
immunosuppressive co-intervention in which control recipients
received a dosage comparison (e.g. high versus low dosage
belatacept).
Types of outcome measures
The following binary outcome measures were considered.
1. Recipient and kidney survival
a. Death (any cause)
b. Loss of kidney transplant (loss of a kidney transplant
requiring return to dialysis)
c. Surviving with a working transplant
2. Incidence and grade of acute rejection
3. Incidence and grade of chronic kidney transplant scarring
4. Incidence of delayed kidney transplant (graM) function (DGF)
5. Incidence of malignancies: all-cause, skin cancers (basal cell
carcinoma (BCC), squamous cell carcinoma (SCC)), PTLD
6. Incidence of infections: cytomegalovirus (CMV viraemia and CMV
disease), polyoma virus (BK viraemia and BK virus-associated
nephropathy), pneumonia, tuberculosis (TB), urinary tract
infection (UTI)
7. Incidence of diabetes
8. Use of antihypertensive agents.
The following continuous outcomes were analysed.
1. Kidney transplant function: measured glomerular filtration rate
(GFR), estimated GFR (eGFR)
2. Cardiovascular and biochemical measures: mean systolic and
diastolic blood pressure (SBP, DBP), total cholesterol, high
density lipoprotein (HDL), non-HDL, low density lipoprotein
(LDL), triglycerides (TGs), serum blood glucose
Search methods for identification of studies
Electronic searches
We searched the Cochrane Renal Group's Specialised Register to
1 September 2014 through contact with the Trials' Search Co-
ordinator using search terms relevant to this review.
The Cochrane Renal Group’s Specialised Register contains studies
identified from:
1. Quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the proceedings of
major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on the
scope of the Cochrane Renal Group. Details of these strategies, as
well as a list of handsearched journals, conference proceedings and
current awareness alerts, are available in the Specialised Register
section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Data collection and analysis
Selection of studies
The search strategies described identified eligible studies. Titles
and abstracts resulting from the searches were then screened by
two authors who independently assessed retrieved abstracts and if
necessary the full text of these studies to determine which studies
satisfied the inclusion criteria. Disagreement about inclusion was
resolved by discussion with a third author. Where more than
one report of a study existed, we grouped reports together and
used the first complete (index) study publication as the primary
data source. We examined any prior or subsequent report for
supplementary outcomes or data to ensure the inclusion of all
relevant information.
Data extraction and management
Data extraction was carried out independently by two authors
using standardised data extraction forms. All data were entered
into RevMan 5.2 and additional statistical analyses were done using
STATA 11.2 soMware (Statacorp, TX, USA).
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?* Participants and personnel* Outcome assessors• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e:ect
For binary outcomes, results were expressed as risk ratios (RR)
with 95% confidence intervals (CI). Where continuous scales of
measurement were used to assess the eGects of treatment we
calculated the mean diGerence (MD) with 95% CI.
Dealing with missing data
We first tried to clarify unclear or missing data by directly
contacting the author of the study report. For the three largest
studies (BENEFIT Study 2008; BENEFIT-EXT 2009; Vincenti 2005)
we held a teleconference with representatives from Bristol Myers
Squibb (the manufacturers of belatacept) in an attempt to access
unpublished data for particular outcomes in certain patient
subgroups. Specifically, we requested data on PTLD stratified by
recipient pre-transplant Epstein Barr virus serostatus and whether
recipients were randomised to the high or low dosage belatacept
treatment arm.
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Assessment of heterogeneity
Heterogeneity amongst studies was analysed using a Cochran Q
test (n-1 degrees of freedom), with an alpha of 0.05 used for
statistical significance and with the I2 test calculated to measure
the proportion of total variation in the estimates of treatment eGect
that was due to heterogeneity beyond chance (Higgins 2003). I2
values of 25%, 50% and 75% correspond to low, medium and high
levels of heterogeneity.
Assessment of reporting biases
We planned to use funnel plots to assess the potential existence of
publication and small study biases but this was not informative due
to the small number of included studies (Higgins 2011).
Data synthesis
We pooled data from individual studies using a random-eGects
model, because the random eGects model provides a more
conservative estimate of eGect in the presence of known or
unknown potential heterogeneity (Higgins 2003).
Subgroup analysis and investigation of heterogeneity
Subgroups analyses were pre-specified and included belatacept
dosage (high or low), kidney donor source (living, standard- or
extended-criteria deceased), calcineurin inhibitor (tacrolimus or
cyclosporine) and pre-transplant Epstein Barr serostatus (negative
or positive). For binary outcomes, we presented results as the
ratio of risk ratios (RRR and 95%CI), showing the proportional
change in risk for the study or participant character listed versus
the reference range comparison. For continuous outcomes, results
were presented as the diGerence in mean diGerences (DMD and
95%CI). Tests of heterogeneity among pooled subgroup estimates
were calculated using univariate random-eGects meta-regression.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
AMer searching the Cochrane Renal Group's Specialised Register
(to 1 September 2014) we identified 642 reports. AMer duplicate
removal and screening of titles and abstracts 250 full-text reports
were assessed. A further 56 reports were excluded (duplicates (43),
study protocols (6), not primary immunosuppression (7)). AMer we
grouped the remaining reports, 13 potential studies (194 reports)
were identified. We identified five included studies (174 reports),
three excluded studies (15 reports), and five ongoing studied (5
reports) (Figure 1).
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Figure 1.   Flow chart showing study selection procedure
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Included studies
We included five studies (174 reports published in 10 journals)
that involved 1535 randomised kidney transplant recipients. One
study (CTOT-10 Study 2013) met our inclusion criteria but did
not contribute data to the meta-analysis because data for key
clinical outcomes were only in abstract form and we were unable
to calculate reliable risk ratios at common time-points. This three
arm phase II study compared belatacept maintenance therapy
(used at an unknown dosage) with either tacrolimus or no CNI in
19 participants induced with either alemtuzumab or basiliximab.
This study was stopped prematurely before one year of follow-up
because of an excess incidence of kidney transplant thrombosis.
Study characteristics
Of the studies included in our meta-analysis, study participants
varied from 89 (Ferguson 2010) to 666 (BENEFIT Study 2008). Four
studies (BENEFIT Study 2008; BENEFIT-EXT 2009; Ferguson 2010;
Vincenti 2005) were multinational, multicentre, parallel design
RCTs with three treatment arms, conducted in Europe and North
America from 2001. Two studies were phase II (Ferguson 2010;
Vincenti 2005) and two were phase III (BENEFIT Study 2008;
BENEFIT-EXT 2009) studies. Duration of completed follow-up varied
from one (Ferguson 2010) to five years. Studies that reported five-
year results (BENEFIT Study 2008; BENEFIT-EXT 2009; Vincenti 2005)
were long-term extensions which only included participants who
were still alive with a functioning kidney at three years, and so
we only present analyses based on outcomes at three years to
avoid the selection bias of these longer-term analyses. Studies
were powered to variably detect non-inferiority or superiority of
belatacept versus CNI for a variety of primary outcomes. Ferguson
2010 and Vincenti 2005 were non-inferiority studies with primary
outcomes of acute rejection at six months. BENEFIT Study 2008
had three co-primary outcomes, powered to detect superiority in
kidney function and non-inferiority in composite patient and graM
survival and incidence of acute rejection. BENEFIT-EXT 2009 was
powered to detect non-inferiority in composite patient and graM
survival, and superiority in kidney function.
Main intervention
Four studies (536 participants; BENEFIT Study 2008; BENEFIT-EXT
2009; Vincenti 2005; Ferguson 2010) used high dose belatacept
regimens and three studies (472 participants; BENEFIT Study 2008;
BENEFIT-EXT 2009; Vincenti 2005) used low dose belatacept. High
dose belatacept recipients received 10 mg/kg on days 1 and 5, then
every two weeks until week 12, then every four weeks until week 24;
and then 5 mg/kg every four weeks thereaMer. Low dose belatacept
participants received 10 mg/kg on days 1 and 5, then every two
weeks until week 4, then every four weeks until week 12 and then
5 mg/kg every four weeks thereaMer.
Belatacept was compared with cyclosporin in three studies (478
participants; BENEFIT Study 2008; BENEFIT-EXT 2009; Vincenti
2005) and tacrolimus in one study (30 participants; Ferguson 2010).
CNI formulation was not clearly stated in any study. Cyclosporin
target levels varied among studies: 100 to 250 ng/mL for years 1 to
3 (BENEFIT Study 2008); 150 to 300 ng/mL in months 0 to 1, 100 to
250 ng/mL in months 2 to 12 (BENEFIT-EXT 2009); 150 to 400 ng/
mL in months 0 to 1, 150 to 300 ng/mL in months 2 to 12 (Vincenti
2005), and for tacrolimus; 8 to 12 ng/mL until day 30, 5 to 10 ng/mL
thereaMer (Ferguson 2010).
Co-interventions
Co-interventions also varied. Three studies (1415 participants;
BENEFIT Study 2008; BENEFIT-EXT 2009; Vincenti 2005) used
basiliximab for induction, and one study (89 participants; Ferguson
2010) used antithymocyte globulin. All participants received
perioperative intravenous (IV) methylprednisolone, although
durations varied: days 0 and 1 (BENEFIT Study 2008; BENEFIT-EXT
2009; Vincenti 2005); and days 0, 1 and 2 (Ferguson 2010). All but
one study (Ferguson 2010) prescribed maintenance prednisone,
tapered variably to no less than 2.5 mg/d by day 15 (BENEFIT
Study 2008), 5 mg to 7 mg/d by months 9 to 12 (BENEFIT-EXT
2009) or no less than 5 mg/d by 6 months (Vincenti 2005). All
studies used mycophenolate mofetil (MMF) (1490 participants)
at a dose of 2 g/d with reductions allowed for symptomatic or
haematological side eGects, with the exception of a subgroup of
26 recipients in the Ferguson 2010 study who instead received
sirolimus. Studies treated episodes of acute rejection similarly.
Acute rejection less severe than BanG 2A criteria received pulsed
intravenous methylprednisolone. BanG 2B or worse acute rejection
was treated with either corticosteroids or T-cell depleting therapy
at the investigator's discretion in three studies (BENEFIT Study
2008; BENEFIT-EXT 2009; Ferguson 2010) whereas one study
routinely used T-cell depleting therapy (Vincenti 2005). Three
studies universally prescribed anti-viral prophylaxis for at least 3
months post transplant or upon initiating T-cell depleting agents
and used Pneumocystis jejuni prophylaxis for 6 months (BENEFIT
Study 2008; BENEFIT-EXT 2009; Ferguson 2010). One study did not
provide details of their bacterial and viral prophylaxis protocols
(Vincenti 2005).
Baseline donor and recipient characteristics
One study (543 participants, BENEFIT-EXT 2009) exclusively
recruited extended criteria deceased donor kidney transplant
recipients. The other three studies recruited a total of 973
living donor or standard-criteria deceased donor kidney recipients
(of which at least 488 were living donor and 485 standard-
criteria deceased donor kidney transplant recipients). Recipients
of extended criteria donor kidneys were older (mean age 56.2
years) than recipients of standard criteria or living donor kidney
transplants (mean age 44.6 years). No study included recipients
younger than 18 years. One study (Ferguson 2010) excluded
recipients who were seronegative for Epstein Barr virus at baseline,
and of the other four studies, one (Vincenti 2005) did not provide
details of participants' serostatus. Three studies (BENEFIT Study
2008; BENEFIT-EXT 2009; Ferguson 2010) included a total of
1176 pre-transplant Epstein Barr virus seropositive and 136 pre-
transplant seronegative participants. Sensitization (determined
by panel reactive antibody titre) did not vary between studies,
with most participants being non-sensitized. Eighteen percent
(BENEFIT Study 2008), 20% (BENEFIT-EXT 2009) and 34% (Ferguson
2010) of participants had diabetes before receiving a kidney
transplant. It was unclear how many participants had pre-existing
diabetes in Vincenti 2005. The most common cause of ESKD was
glomerulonephritis; 22% (BENEFIT Study 2008), 26% (BENEFIT-EXT
2009) and 35% (Vincenti 2005) of kidney transplant recipients.
Similar proportions of recipients had ESKD caused by diabetes,
hypertension, and polycystic kidney disease amongst studies.
Outcome ascertainment and definitions
Data for acute rejection and chronic kidney scarring were obtained
from kidney transplant biopsies, scored according to the BanG '97
Belatacept for kidney transplant recipients (Review)
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diagnostic categories for kidney allograM biopsies. Four studies
(BENEFIT-EXT 2009; BENEFIT Study 2008; Ferguson 2010; Vincenti
2005) performed indication biopsies based on protocol-defined
reasons for clinical suspicion of acute rejection. Three studies
performed pre-specified protocol transplant biopsies at 12 months
(BENEFIT-EXT 2009; BENEFIT Study 2008; Vincenti 2005). Severe
acute rejection included kidney biopsies scored as BanG IIA or
worse. Chronic kidney scarring included mild (aGecting < 25% of
the kidney cortex), moderate (25 to 50% of the cortex), and severe
changes (aGecting > 50% of the cortex).
Excluded studies
We excluded three studies (Kamar 2013; Kirk 2012; Rostaing
2011) in which belatacept was not used in a primary
immunosuppression regimen, but rather as a switch from
conventional immunosuppression at some time distant from
kidney transplantation.
Ongoing studies
Five ongoing studies were identified that met inclusion criteria
but have not yet published any results (EudraCT2006-00311417;
EudraCT2011-00616240; EudraCT2013-00117820; NCT01729494;
NTR4242).
Risk of bias in included studies
Study methodology reporting is summarised in Figure 2.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
Of the studies included in meta-analysis, two reported adequate
sequence generation (BENEFIT Study 2008; BENEFIT-EXT 2009) and
two described the process in insuGicient detail to allow a confident
judgement of the risk of bias (Ferguson 2010; Vincenti 2005).
Four studies reported adequate allocation concealment (BENEFIT
Study 2008; BENEFIT-EXT 2009; Ferguson 2010; Vincenti 2005). We
deemed no study to be at high risk of selection bias.
Blinding
We judged that all four studies (BENEFIT Study 2008; BENEFIT-
EXT 2009; Ferguson 2010; Vincenti 2005) were at low risk of
performance and detection bias despite the blinding of neither
participants nor outcome assessors. Belatacept was administered
intravenously, and CNI orally with no placebo infusion described
in the study protocols. However, the outcomes assessed were
objective measures recorded by standardized and validated
methods which we thought were unlikely to be influenced by a lack
of blinding (e.g. estimated GFR).
Incomplete outcome data
All studies (BENEFIT Study 2008; BENEFIT-EXT 2009; Ferguson 2010;
Vincenti 2005) adequately addressed incomplete outcome data
for up to three years post kidney transplant. Long-term extension
data was presented between three and five years following kidney
transplant in three studies (BENEFIT-EXT 2009; BENEFIT Study 2008;
Vincenti 2005). We considered that this data was biased by survival
of the kidney transplant recipients themselves (and their kidney
transplants) to at least three years following transplant and so
presented our analyses based on three year outcome data available
for the full intention-to-treat populations.
Selective reporting
Two studies were at high risk of selective reporting (BENEFIT
Study 2008; BENEFIT-EXT 2009). This arose because key outcomes
were not uniformly reported at standardized time-points amongst
studies including for key outcomes such as graM loss, PTLD and
diabetes. In addition, for clinical outcomes where we expected
that the risk of particular adverse events might vary by specific
subgroups of patients (for example the risk of PTLD by a recipient's
pre-transplant Epstein Barr virus status), data was oMen not
published at all or not published in enough detail to contribute
to data synthesis. Finally, even aMer directly requesting missing
Belatacept for kidney transplant recipients (Review)
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data from data custodians (BENEFIT-EXT 2009; BENEFIT Study
2008), we received no data that was not already available in the
public domain. The other two studies (Ferguson 2010; Vincenti
2005) provided insuGicient information to permit judgement and so
remain unclear in their potential for reporting bias.
Other potential sources of bias
Bristol Myers Squibb - the manufacturer of belatacept - funded
three of the studies (BENEFIT Study 2008; BENEFIT-EXT 2009;
Vincenti 2005).
E:ects of interventions
See: Summary of findings for the main comparison
Belatacept versus calcineurin inhibitors
Up to three years aMer a kidney transplant, belatacept and CNI-
treated kidney recipients were at similar risk of dying (Analysis
1.1.1 (4 studies, 1516 recipients): RR 0.75, 95% CI 0.39 to 1.44; I2 =
38%), losing their kidney transplant (Analysis 1.1.2 (4 studies, 1516
recipients): RR 0.91, 95% CI 0.61 to 1.38; I2 = 0%) and surviving
with a functioning kidney transplant (Analysis 1.2 (4 studies 1516
recipients): RR 1.01, 95% CI 0.96 to 1.06; I2 = 42%).
Acute rejection occurred with similar incidence in recipients
who received belatacept and CNI (Analysis 1.3.1 (4 studies, 1516
participants): RR 1.56, 95% CI 0.85 to 2.86; I2 = 63%) with no
diGerence in the chances of the rejection being severe (Analysis
1.3.2 (2 studies, 194 recipients): RR 1.02, 95% CI 0.76 to 1.37; I2 =
34%). Overall, chronic kidney scarring was significantly reduced by
28% (Analysis 1.3.3 (3 studies, 1360 recipients): RR 0.72, 95% CI 0.55
to 0.94; I2 = 63%) in belatacept-treated recipients but not severe
chronic rejection (Analysis 1.3.4 (3 studies, 1360 recipients): RR 0.75,
95% CI 0.42 to 1.32; I2 = 0%).
Belatacept-treated kidney transplant recipients had better kidney
function (Analysis 1.4.1 (measured GFR (3 studies 1083 recipients):
MD 10.89 mL/min/1.73 m2, 95% CI 4.01 to 17.77; I2 = 79%) (Analysis
1.4.2 (eGFR (4 studies, 1143 recipients): MD 9.96 mL/min/1.73 m2,
95% CI 3.28 to 16.64; I2 = 79%), lower blood pressure (Analysis
1.4.3 (systolic (2 studies, 658 participants): MD -7.51 mm Hg, 95%
CI -10.77 to -4.46; I2 = 0%) (Analysis 1.4.4 (diastolic (2 studies, 658
recipients): MD -3.07 mm Hg, 95% CI -4.83 to -1.31; I2 = 0%) and had
a smaller rise in non-HDL cholesterol (Analysis 1.4.5 (3 studies, 1101
participants): MD -12.25 mg/dL, 95% CI -17.93 to -6.57; I2 = 11%)
and triglycerides during the study (Analysis 1.4.6 (3 studies, 1101
recipients): MD -24.09 mg/dL, 95% CI -44.55 to -3.64; I2 = 69%) than
recipients who received a CNI.
The risk of any malignancy (Analysis 1.5.1 (4 studies, 1516
recipients): RR 1.00, 95% CI 0.58 to 1.72; I2 = 0%) and PTLD (Analysis
1.5.2 (4 studies, 1516 recipients): RR 2.79, 95% CI 0.61 to 12.66; I2 =
0%) and was similar in both treatment arms.
Any infection (Analysis 1.6.1 (4 studies, 1516 recipients): RR 0.98,
95% CI 0.87 to 1.09; I2 = 49%) and serious infections (Analysis 1.6.2
(2 studies, 1209 recipients): RR 0.96, 95% CI 0.83 to 1.12; I2 = 0%)
occurred with similar incidence. Specifically, tuberculosis (Analysis
1.6.3 (2 studies, 1209 recipients): RR 3.96, 95% CI 0.72 to 21.67; I2
= 0%), CMV disease (Analysis 1.6.4 (2 studies, 1209 recipients): RR
1.51, 95% CI 0.91 to 2.50; I2 = 0%), and polyoma-virus related (BK)
nephropathy (Analysis 1.6.5 (1 study, 666 recipients): RR 0.25, 95%
CI 0.05 to 1.35) were equally likely in recipients receiving belatacept
as those receiving a CNI.
We observed a 39% reduction in the risk of developing new-onset
diabetes (Analysis 1.7.1 (4 studies, 1049 participants): RR 0.61, 95%
CI 0.40 to 0.93; I2 = 0%) and a 17% reduction in the number of kidney
transplant recipients who needed to take one or two blood pressure
medicines following their transplant (Analysis 1.7.2 (2 studies, 755
recipients): RR 0.79, 95% CI 0.67 to 0.92; I2 = 0%) amongst those
who received belatacept versus those who received a CNI. There
was no diGerence between the groups for those patients requiring
three or blood pressure medicines (Analysis 1.7.3 (3 studies, 1298
recipients): RR 0.83, 95% CI 0.65 to 1.07; I2 = 51%).
Presence of new donor-specific antibodies was no diGerent
between recipients of belatacept or a CNI (Summary of findings for
the main comparison (2 studies, 1209 recipients): RR 0.41, 95% CI
0.01 to 1.31). Delayed graM function occurred at a similar rate in
kidney transplant recipients who received belatacept to recipients
who received a CNI (Summary of findings for the main comparison
(2 studies, 1209 recipients): RR 0.93, 95% CI0.79 to 1.09).
High versus low dosage belatacept
Three studies (949 recipients) compared high versus low dosage
belatacept (BENEFIT Study 2008; BENEFIT-EXT 2009; Vincenti 2005).
High and low dosage treated kidney transplant recipients had
similar risks of dying (Analysis 2.1.1 (3 studies, 949 recipients): RR
1.24, 95% CI 0.75 to 2.06; I2 = 0%), losing their kidney transplant
(Analysis 2.1.2 (3 studies, 949 recipients): RR 0.96, 95% CI 0.59 to
1.56; I2 = 0%), and surviving with a functioning kidney at up to three
years (Analysis 2.2 (3 studies, 949 recipients): RR 0.98, 95% CI 0.95
to 1.02; I2 = 0%).
Acute rejection (Analysis 2.3.1 (3 studies, 949 recipients): RR 1.17,
95% CI 0.88 to 1.55; I2 = 0%), severe acute rejection (Analysis 2.3.2
(2 studies, 152 recipients): RR 1.28, 95% CI 0.67 to 2.43; I2 = 88%),
chronic kidney scarring (Analysis 2.3.3 (3 studies, 910 recipients):
RR 0.94, 95% CI 0.74 to 1.20; I2 = 27%), and severe chronic kidney
scarring (Analysis 2.3.4 (3 studies, 910 recipients): RR 0.77, 95% CI
0.34 to 1.75; I2 = 10%) occurred with similar incidence in with either
dosage.
There was no diGerence in kidney transplant function (Analysis
2.4.1 (measured GFR (3 studies, 735 recipients): RR 0.37 mL/
min/1.73m2, 95% CI -3.49 to 4.23; I2 = 12%) (Analysis 2.4.2, eGFR (3
studies, 747 recipients): MD 0.13 mL/min/1.73m2, 95% CI -2.94 to +
3.20; I2 = 0%), blood pressure (Analysis 2.4.3 (systolic (2 studies 659
recipients): MD +1.16 mm Hg, CI -1.33 to + 3.66; I2 = 0%) (Analysis
2.4.4 (diastolic (2 studies 659 recipients): MD 0.00 mm Hg, 95% CI
-1.52 to +1.52; I2 = 0%), change in non-HDL cholesterol (Analysis
2.4.5 (2 studies, 671 recipients), MD 0.59 mg/dL, 95% CI -5.54 to
+6.72; I2 = 0%), or change in triglycerides during the study (Analysis
2.4.6 (2 studies, 671 recipients): MD 8.82 mg/dL, 95% CI -6.63 to
24.28; I2 = 0%) in recipients who received high dosage belatacept
compared with those who received low dosage belatacept.
Any malignancy (Analysis 2.5.1 (3 studies, 949 participants): RR 1.27,
95% CI 0.52 to 3.13; I2 = 0%) and PTLD (Analysis 2.5.2 (2 studies, 949
recipients): RR 1.25, 95% CI 0.39 to 3.99; I2 = 0%) were equally likely
in recipients treated with high dosage belatacept as in recipients
treated with low dosage belatacept.
Belatacept for kidney transplant recipients (Review)
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Any infection (Analysis 2.6.1 (3 studies, 949 recipients): RR 0.98,
95% CI 0.92 to 1.04; I2 = 0%) and serious infections (Analysis 2.6.2
(2 studies, 804 recipients): RR 0.89, 95% CI 0.73 to 1.09; I2 = 17%)
occurred with similar incidence. Tuberculosis (Analysis 2.6.3 (2
studies, 804 recipients): RR 0.99, 95% CI 0.23 to 4.17; I2 = 31%), CMV
disease (Analysis 2.6.4 (3 studies, 949 recipients): RR 1.02, 95% CI
0.74 to 1.40; I2 = 0%), and BK nephropathy (Analysis 1.6.5 (1 study,
445 recipients): RR 1.03, 95% CI 0.06 to 16.40) were equally likely in
recipients receiving high or low dosage belatacept.
We observed no diGerence in the eGect of dosage on the incidence
of new-onset diabetes (Analysis 2.7.1 (3 studies, 739 recipients): RR
0.91, 95% CI 0.33 to 2.51; I2 = 48%). Use of one or two (Analysis
2.7.2 (1 study, 445 recipients): RR 1.15, 95% CI 0.91 to 1.45) or three
or more blood pressure medicines (Analysis 2.7.3 (2 studies, 804
recipients): RR 1.10, 95% CI 0.91 to 1.32; I2 = 0%) were similar in the
diGerent belatacept dosage groups.
Variation in treatment e:ect by key study intervention and
participant characteristics
Subgroup analyses were performed for main clinical outcomes
to examine whether key study and participant characteristics
modified overall results. Stratified into high and low belatacept
dosage groups, there was no diGerence in treatment eGects
between groups for comparisons of belatacept versus CNI for
recipient and graM survival (RRR 0.99, 95% CI 0.92 to 1.07, test for
diGerence = 0.88), acute rejection (RRR 1.18, 95% 95% CI 0.49 to
2.81, test for diGerence = 0.71), PTLD (RRR 1.06, 95% CI 0.11 to
9.80, test for diGerence = 0.96 or eGFR (DMD -0.25 mL/min/1.73
m2, 95% CI -9.18 to +8.69, test for diGerence = 0.96). The relative
eGects of belatacept versus CNI did not vary between extended-
criteria versus living or standard-criteria donor kidney recipients
for recipient and graM survival (RRR 1.03, 95% CI 0.88 to 1.21, test
for diGerence = 0.69) or eGFR (DMD -1.21 mL/min/1.73 m2, 95% CI
-20.1 to +17.7, test for diGerence = 0.90). Comparing the relative
eGects of tacrolimus and cyclosporin against belatacept, there was
no diGerence in recipient and graM survival (RRR 0.89, 95% CI 0.74
to 1.06, test for diGerence = 0.11), eGFR (DMD -0.95, 95% CI -19.4
to +17.5, test for diGerence = 0.92) or acute rejection (RRR 1.71
95% CI 0.01 to 393.06, test for diGerence = 0.71), though estimates
were imprecise for rare events such as acute rejection. Epstein Barr
virus serostatus did not appear to aGect the relative risk of PTLD
(RRR 1.49, 95% CI 0.15 to 14.76, test for diGerence = 0.73), though
again the imprecision of this estimate or eGect made meaningful
interpretation diGicult.
Sensitivity analyses
The small number of included studies precluded meaningful
sensitivity analyses.
Reporting bias
We intended to examine funnel plots for asymmetry to detect
publication bias, small-study eGects and diGerences in estimates of
eGect arising from study methodological quality. However, this was
not informative due to the small number of included studies.
D I S C U S S I O N
The availability of new biologic agents like belatacept (which
may avoid the unwanted side-eGects of currently used
immunosuppression regimens) means that established treatment
strategies require re-evaluation. Transplant clinicians need reliable
estimates of the relative benefits and harms of treatment with
belatacept, particularly because high rates of PTLD have been
reported when belatacept is used at high dosage or in recipients
who are Epstein Barr virus seronegative before their kidney
transplant.
Summary of main results
Treatment with belatacept was associated with similar rates of
death, kidney transplant survival and acute rejection to treatment
with a CNI in the first three years following a kidney transplant.
Belatacept-treated kidney transplant recipients had less new-onset
diabetes aMer transplant, lower blood pressure, better kidney
transplant function and less chronic kidney scarring seen on
kidney biopsies than CNI-treated kidney transplant recipients.
PTLD occurred at similar rates in recipients treated with high and
low dosage belatacept and did not appear to significantly diGer in
incidence between Epstein Barr virus seropositive and seronegative
kidney transplant recipients. Estimates of relative eGects in
subgroups of patients receiving high versus low dosage belatacept
and in subgroups who were Epstein Barr virus seropositive
versus seronegative were imprecise because of selective outcome
reporting of PTLD. All other malignancies and infections reported
occurred at similar rates. The main deficiency in the published data
was that outcomes were reported selectively and inconsistently
which limited between-study comparisons and the opportunities
for data synthesis.
Overall completeness and applicability of evidence
This is the first synthesis of data from all studies evaluating
the benefits and harms of primary immunosuppression with
belatacept. We undertook an extensive literature search and
sought data from every report of each study, identifying 12% of
included reports from hand-searching of conference abstracts, and
contacting triallists and study data custodians directly where data
was missing or unclear. We also explicitly examined important
subgroup eGects to explore potential diGerences that might arise
from immunosuppressive co-interventions, donor and recipient
characteristics. There were data gaps, particularly relating to
PTLD, belatacept dosage and Epstein Barr virus serostatus. Despite
direct communication with Bristol-Myers-Squibb over a number
of months and requests for unpublished data (specifically for
particular patient subgroups where data was sparse) we did not
obtain any new informative data which was not already in the
public domain and so the data we present is subject to outcome
reporting bias. Further data is being collected in three post-
marketing clinical studies required by the FDA as a condition of
belatacept licence approval which may help address some current
data deficiencies. The first study is the creation of a belatacept
registry which will collect data on the incidence of PTLD. The
second study will analyse the pattern of use of belatacept in
routine clinical practice using the United Network for Organ Sharing
database, whilst the third will use these data to compare rates
of PTLD between belatacept and CNI-based immunosuppression
regimens.
Although kidney transplant recipients included in studies were
generally representative of the ESKD who receive kidney
transplants, there were important exceptions. Recipients aged less
than 18 years old were excluded from all studies, immediately
limiting the generalisability of our findings to the adult transplant
Belatacept for kidney transplant recipients (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
12
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
population. Approximately 40% of patients on the United States'
active kidney transplant waiting list are sensitised with a PRA of
> 20% (OPTN 2013). In our review, recipients were generally non-
sensitized. Sensitized patients spend more time on the kidney
transplant waiting list, have an increased risk of acute rejection and
are at higher risk of producing donor-specific antibodies following
a kidney transplant. These all increase the risk of death and kidney
transplant loss and so the eGectiveness of belatacept in recipients
with levels of PRA > 20% may not be represented by our data (Gloor
2009; Hidalgo 2009). Thirty percent of standard criteria kidney
transplants performed in Australia in 2010 were from living donors
(ANZDATA 2012). In our study, 50% of recipients received a standard
criteria kidney, but we could not analyse outcomes separately for
living and deceased donor kidney recipients by drug treatment
allocation groups as only the overall number receiving a living
donor or a deceased donor was provided in reports. Donor factors
which significantly aGect deceased donor transplant outcomes
have lesser eGects on living donor transplant outcomes (Rao 2009).
The main limitation in applying our findings to contemporary
clinical practice is that belatacept still remains relatively untested
against tacrolimus. Eighty six percent of new kidney transplant
recipients now receive tacrolimus for primary immunosuppression
(ANZDATA 2012). Only two percent (30 participants) of kidney
transplant recipients included in our meta-analysis received
tacrolimus (Ferguson 2010). Tacrolimus and cyclosporine vary in
their eGects on blood pressure, lipids, blood sugar regulation and
risk of infection with polyoma virus, and so the relative eGects
of belatacept and CNI we observed may not be replicated when
belatacept is used in mainstream clinical practice (Webster 2005).
Quality of the evidence
Overall study quality was good (Figure 2), though selective outcome
reporting was suspected in two of the included studies with
data for the main safety concern surrounding belatacept – PTLD
in diGerent belatacept dosage and Epstein Barr virus serostatus
groups – mainly derived from FDA licensing documentation and
not the original study reports (Figure 3). Even aMer directly
requesting data for these subgroups from Bristol Myers Squibb,
data were not provided. The potential for selective outcome
reporting bias remains, and estimates of eGect for key clinical
outcomes (including PTLD in diGerent patient and dosage groups)
remain imprecise. Opportunities for synthesizing data were also
limited by incomplete reporting of statistical data for key recipient
and patient-centred outcomes. These included data for blood
pressure, physical and mental well-being scores, symptom distress
scores, and health-related quality of life (Dobbels 2014). The design,
conduct and analysis of included studies were frequently diGicult
to assess because of omission of important methodological detail
in the study reports. No single study adequately addressed all
domains of the risk of bias assessment (Figure 2) despite using
multiple sources of data. It is therefore impossible to exclude the
possibility that some internal biases may be present in the results
of the meta-analysis (Begg 1996; Moher 2009).
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Belatacept is a valid alternative to CNI for the maintenance
immunosuppression of kidney transplant recipients, though some
uncertainty remains about its eGects in specific subgroups of
patients. Pragmatically, the balance between benefits and harms
of treatment with belatacept might favour treatment of transplant
candidates in whom there is concern about the side-eGects of
CNI, for example in recipients with pre-transplant impaired glucose
tolerance or poorly controlled hypertension. Until further data
becomes available for core outcomes at standardized time-points,
the precision of estimates of eGects for some outcomes will remain
poor, and so belatacept must be used carefully, and adverse events
reported routinely. The medium to long-term eGect of belatacept
on the incidence of cancers remains largely unknown and ongoing
surveillance using linked kidney and cancer registry data and
data from post-marketing cohort studies must be integrated into
our current understanding of benefits and harms when informing
clinical decision making.
Implications for research
There are three main implications for future research. Firstly,
triallists should comprehensively report their results according
to existing international guidelines, and publishing journals and
editors should rigorously enforce these standards (Begg 1996;
Masson 2013). The FDA's limited approval to use belatacept only
at low dosage in Epstein Barr seropositive kidney transplant
recipients means that future studies are unlikely to help clarify
the uncertain eGects of high dosage belatacept, or the use of
belatacept at any dosage in Epstein Barr seronegative recipients.
Unpublished study data should be made available for sharing in a
data repository, so as to maximise the usefulness and usage of data
and promote transparency (Godlee 2012). These initiatives would
allow more informative synthesis and between-study comparisons,
and would help address some of the current deficiencies in the
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literature regarding the eGectiveness of belatacept in specific
recipient subgroups. Secondly, contemporary studies should
reflect contemporary clinical practice, and new studies must
test belatacept against tacrolimus. Finally, surrogate markers of
definitive endpoints in studies of kidney transplantation remain un-
validated and researchers should conduct longer term studies with
suGicient power to demonstrate significant diGerences in eGect for
core clinical and patient-centred outcomes (White 2010).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Study duration: January 2006 to June 2008• Duration of follow-up: 12 months post-transplant
Participants • Country: International (Europe, North America, Australasia)• Setting: 100 centres• Patients > 18 y; living/standard-criteria donor; cold ischaemic time < 24 h• PRA > 20% in 10% participants• Epstein Barr virus: positive (577); negative (89)• Pre-existing diabetes: 18%• Donors: living (386); deceased (280)• Number: high dose group (219); low dose group (226); CSA group (221)• Mean age (years): high dose group (43.6); low dose group (42.6); CSA group (43.5)• Sex (M/F): high dose group (115/104); low dose group (147/79); CSA group (166/55)• Exclusion criteria: recipients of extended criteria kidneys; prior or concurrent nonrenal solid organ
transplants; first-time patients with a PRA ≥ 50% or retransplants with a panel reactive antibody ≥ 30%
Interventions High dose belatacept group
• 10 mg/kg on days 1, 5, and weeks 2, 4, 6, 8, 10, 12, 16, 20, 24• 5 mg/kg every 4 weeks for months 7 to 12
BENEFIT Study 2008 
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Low dose belatacept group
• 10 mg/kg on days 1, 5, and weeks 2, 4, 8, 12• 5 mg/kg every 4 weeks for months 3 to 12
CSA group
• Initial dose: 4 to 10 mg/kg adjusted to 150 to 300 ng/mL (0 to 1 months)• 100 to 250 ng/mL (2 to 12 months)
Co-interventions (all groups)
• Basiliximab: 20 mg on days 0 and 4• Methylprednisolone: 500 mg on day 0; 250 mg on day 1• MMF: 2 g/d• Prednisone: tapering regimen from day 2
Outcomes • Mortality• GraM loss• Patient and graM survival• Measured and eGFR• Incidence and grade of acute rejection• Incidence and grade of chronic allograft nephropathy• Incidence of malignancy• Change in lipids (non-HDL cholesterol, triglycerides) from baseline• BP and use of antihypertensive medications (≥ 1, ≥ 3)• Incidence of diabetes• Infections: UTI, pneumonia, CMV, TB, BK virus
Notes • Phase III clinical study• CMV and pneumocystis prophylaxis given• Acute rejection treatment: ≤ BanG 2A, methylprednisolone; ≥ BanG 2B, methylprednisolone or T-cell
depletion
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random allocation by computer-generated sequence
Allocation concealment
(selection bias)
Low risk Central allocation
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Blinded to belatacept dosage allocation but not to whether recipients received
belatacept or CNI. No dummy IV infusion for recipients allocated CNI
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT to 3 years following kidney transplant
Selective reporting (re-
porting bias)
High risk Reports of PTLD by dosage and Epstein Barr virus status from FDA approval re-
ports, not original manuscripts and data not provided despite directly request-
ing from Bristol Myers Squibb
Other bias High risk Funded by Bristol Myers Squibb
BENEFIT Study 2008  (Continued)
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Methods • Study design: parallel RCT• Duration of study: March 2005 and is still ongoing• Duration of follow-up: 3 years
Participants • Country: International (Europe, North America, Australasia)• Setting: 79 centres• Patients > 18 y who received an extended-criteria deceased donor kidney• PRA: > 20% in 1.5% recipients• Epstein Barr virus: positive (510); negative (47)• Pre-existing diabetes: 20%• Number: high dose group (184); low dose group (175); CSA group (184)• Mean age ± SD (years): high dose group (56.7 ± 13); low dose group (53.1 ± 12); CSA group (55.7 ± 12)• Sex (M/F): high does group (120/64); low dose group (130/45); CSA group (116/68)• Exclusion criteria: NS
Interventions High dose belatacept group
• 10 mg/kg on days 1, 5, and weeks 2, 4, 6, 8, 10, 12, 16, 20, 24• 5 mg/kg every 4 weeks for months 7 to 12
Low dose belatacept group
• 10 mg/kg on days 1, 5, and weeks 2, 4, 8, 12• 5 mg/kg every 4 weeks for months 3 to 12
CSA group
• Initial dose: 4 to 10 mg/kg adjusted to 150 to 300 ng/mL (0 to 1 months)• 100 to 250 ng/mL (2 to 12 months)
Co-interventions (all groups)
• Basiliximab: 20 mg on days 0 and 4• Methylprednisolone: 500 mg on day 0; 250 mg on day 1• MMF: 2 g/d• Prednisone: tapering regimen from day 2
Outcomes • Mortality• GraM loss• Patient and graM survival• Measured and eGFR• Incidence and grade of acute rejection• Incidence and grade of chronic allograft nephropathy• Incidence of malignancy• Change in lipids (non-HDL cholesterol, triglycerides) from baseline• BP and use of antihypertensive medications (≥ 1, ≥ 3)• Incidence of NODAT• Infections: UTI, pneumonia, CMV, TB
Notes • Definition of extended criteria donor: donors ≥ 60 y; or donors ≥ 50 y and had at least two other risk
factors (cerebrovascular accident, hypertension or SCr > 1.5 mg/dL); or an anticipated cold ischaemia• Phase III clinical study• CMV and pneumocystis prophylaxis given
BENEFIT-EXT 2009 
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• Acute rejection treatment: ≤ BanG 2A, methylprednisolone; ≥ BanG 2B, methylprednisolone or T-cell
depletion
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random allocation by computer-generated sequence
Allocation concealment
(selection bias)
Low risk Central allocation
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Blinded to belatacept dosage allocation but not to whether recipients received
belatacept or CNI. No dummy IV infusion for recipients allocated CNI
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT to 3 years following kidney transplant
Selective reporting (re-
porting bias)
High risk Standard deviations missing for continuous outcomes (eGFR). Reports of PTLD
by dosage and Epstein Barr virus status from FDA approval reports, not origi-
nal manuscripts and data not provided despite directly requesting from Bristol
Myers Squibb
Other bias High risk Funded by Bristol Myers Squibb
BENEFIT-EXT 2009  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Mean duration of follow-up: 40 weeks
Participants • Country: USA• Setting: phase II, multi-centre study• First living or standard-donor criteria kidney recipients; aged 18 to 65 y• PRA: < 30%• Epstein Barr virus seronegative: none• Number: group 1 (6); group 2 (6); group 3 (7)• Age: NS• Sex (M/F): NS• Exclusion criteria: extended-criteria donor kidneys
Interventions Group 1 (control)
• Alemtuzumab induction, tacrolimus maintenance
Group 2
• Alemtuzumab induction, belatacept maintenance
Group 3
• Basiliximab induction, 3 months taper of tacrolimus, belatacept maintenance
CTOT-10 Study 2013 
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Co-interventions (all groups)
• Short-term prednisone and maintenance mycophenolate mofetil 1g twice daily
Outcomes • Primary outcome: incidence of adverse events and serious adverse events
Notes • Sponsored by National Institute of Allergy and Infectious Diseases• Halted prematurely (mean 40 weeks follow-up) because four recipients had vascular thrombosis,
three lost their graMs and there was a high incidence of acute rejection
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described in abstracts
Allocation concealment
(selection bias)
Unclear risk Not described in abstracts
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Open label
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Outcomes for all enrolled patients described in detail at time of study termina-
tion
Selective reporting (re-
porting bias)
Low risk Adverse events reported fully in keeping with primary outcomes stated in pro-
tocol, though only in abstract form
Other bias Unclear risk Insufficient data published for reliable judgment
CTOT-10 Study 2013  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: July 2007 to May 2009• Duration of follow-up: 12 months
Participants • Country: international (USA, Spain, Italy)• Setting: 25 centres• Patients > 18 y; standard-criteria deceased or living donor; recipients all Epstein Barr virus positive• Number: belatacept-MM group (33); belatacept-SRL group (26); CNI group (30)• Mean age ± SD (years): belatacept-MMF group (49.2 ± 11.1); belatacept-SRL group (52.7 ± 10.8); CNI
group (53.6 ± 13.2)• Sex (M/F): belatacept-MM group (25/8); belatacept-SRL group (20/6); CNI group (22/8)• Exclusion criteria: recipients of extended criteria donor kidneys according to an expanded UNOS def-
inition; any prior or concurrent nonrenal solid organ transplant; high immunological risk features in-
cluding current (pretransplant) panel-reactive antibodies (PRA) ≥ 50% (> 30% if retransplant) or with
any prior graM loss due to acute rejection; underlying kidney disease that could recur in the allograft;
infection; HIV, hepatitis B or hepatitis C virus, or latent tuberculosis; history of malignancy in the pre-
vious 5 y (other than non-melanoma skin cancer cured by resection); seronegative for Epstein Barr
virus (EBV) or with a body mass index > 35 kg/m2; Female patients of childbearing potential not using
an adequate method of contraception during the study
Ferguson 2010 
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Interventions Belatacept-MMF group
• Belatacept* 10 mg/kg on days 1, 5 and weeks 2, 4, 6, 8, 10, 12, 16, 20, 24* 5 mg/kg every 4 weeks for months 7 to 12• MMF: 2 g/d
Belatacept-SRL group
• Belatacept* 10 mg/kg on days 1, 5 and weeks 2, 4, 6, 8, 10, 12, 16, 20, 24* 5 mg/kg every 4 weeks for months 7 to 12• SRL: 5 mg/d, levels 7 to 12 ng/mL to month 6, 5 to 10 ng/mL thereafter
CNI group
• Tacrolimus: 0.1 mg/kg/d adjusted to keep trough levels 8 to 12 ng/mL to day 30, 5 to 10 ng/mL there-
after• MMF: 2 g/d
Co-interventions (both groups)
• Thymoglobulin: 1.5 mg/kg on days 0 to 3• Methylprednisolone IV: 500 mg, 250 mg, 125 mg and 60 mg on days 0 to 3 respectively
Outcomes • Patient and graM survival• eGFR• Incidence and grade of acute rejection• Incidence and grade of chronic allograft nephropathy• Incidence of malignancy• Change in lipids (HDL, LDL, non-HDL and total cholesterol, triglycerides) from baseline• Use of antihypertensive medications (≥ 3)• Incidence of NODAT• Infections: any; serious
Notes • Belatacept groups combined for meta-analyses• Phase II clinical study. CMV and pneumocystis prophylaxis given• Acute rejection treatment: ≤ BanG 2A, methylprednisolone; ≥ BanG 2B, methylprednisolone or T-cell
depletion
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)
Low risk Central, interactive voice response system
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Blinded to belatacept dosage allocation but not to whether recipients received
belatacept or CNI. No dummy IV infusion for recipients allocated CNI
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT to 3 years
Ferguson 2010  (Continued)
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Selective reporting (re-
porting bias)
Low risk Outcomes reported match protocol
Other bias Unclear risk Not described
Ferguson 2010  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: March 2001 to December 2003• Duration of follow-up: 12 months
Participants • Country: international (Europe, North America)• Setting: 22 centres• Patients > 18 y; standard criteria donor• Number: high dose group (74); low dose group (71); CSA group (73)• Mean age (years): high dose group (46.5); low dose group (42.1); CSA group (46.1)• Sex (M/F): high dose group (54/20); low dose group (48/23); CSA group (49/24)• Exclusion criteria: underlying kidney disease in the recipient that could recur in the allograft, including
focal and segmental glomerulosclerosis, type I or II membranoproliferative glomerulonephritis, the
haemolytic–uraemic syndrome, and thrombotic thrombocytopenic purpura; active hepatitis B or C
or any other infection that would normally preclude transplantation; human immunodeficiency virus
infection; a history of or evidence of cancer; a positive T-cell lymphocytotoxic crossmatch with the use
of donor lymphocytes and recipient serum; a history of drug or alcohol abuse or psychotic disorders;
previous treatment with basiliximab; use of any investigational drug within 30 days before the visit on
day 1; a donor age of more than 60 y or < 6 y; a donor whose heart was not beating at the time of organ
harvest; and a cold-ischaemia time of more than 36 hours
Interventions High dose belatacept group
• 10 mg/kg for days 1, 5, and weeks 2, 4, 6, 8, 10, 12, 16, 20, 24• 5 mg/kg every 4 or 8 weeks for months 7 to 12
Low dose belatacept group
• 10 mg/kg days for 1, 5, and weeks 2, 4, 8, 12• 5 mg/kg every 4 or 8 weeks for months 3 to 12
Cyclosporin group
• Initial dose: 4 to 10 mg/kg adjusted to 150 to 400 ng/mL (0 to 1 months); 150-300 ng/mL (2 to 12
months)
Co-interventions (all groups)
• Basiliximab: 20 mg days 0 and 4• Methylprednisolone: 500 mg on day 0, 250 mg on day 1• MMF: 2 g/d• Prednisolone: tapering regimen from day 2
Outcomes • Mortality• GraM loss• Measured and eGFR• Incidence and grade of acute rejection• Incidence and grade of chronic allograft nephropathy• Incidence of malignancy
Vincenti 2005 
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• Change in lipids (non-HDL cholesterol, triglycerides) from baseline• Incidence of NODAT• Infections: Any, UTI, CMV
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)
Low risk Randomisation performed centrally
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Blinded to dose of belatacept. Unblinded to cyclosporin administration
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT to 3 years. Loss to follow-up small
Selective reporting (re-
porting bias)
High risk Epstein Barr virus serostatus not reported (except in FDA report of belatacept
approval)
Other bias High risk Supported by Bristol-Myers Squibb
Vincenti 2005  (Continued)
BP - blood pressure; CMV - cytomegalovirus; CNI - calcineurin inhibitor; eGFR - estimated GFR; GFR - glomerular filtration rate; HDL - high-
density lipoprotein; ITT - intention-to-treat; LDL - low-density lipoprotein; MMF - Mycophenolate mofetil; NODAT - new onset diabetes aMer
transplantation; NS - not stated; PRA - panel reactive antibodies; PTLD - post-transplant lymphoproliferative disorder; RCT - randomised
controlled trial; SCr - serum creatinine; SRL - sirolimus; TB - tuberculosis; UTI - urinary tract infection
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Kamar 2013 Not primary immunosuppressive regimen; switch from CNI-based regimen to belatacept
Kirk 2012 Not primary immunosuppressive regimen
Rostaing 2011 Not primary immunosuppressive regimen; switch from CNI-based regimen to belatacept versus
continued CNI at 12 months
CNI - calcineurin inhibitor
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A randomized, open-label, multi-center, parallel-group study of belatacept-based corticos-
teroid-free regimens in renal transplant
Methods Open label RCT
EudraCT2006-00311417 
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Participants Adult recipients of a living or deceased-donor kidney transplant
Interventions Belatacept versus tacrolimus, both with thymoglobulin and MMF
Outcomes Primary: incidence acute rejection at 6 months Secondary: severity of rejection, death, metabol-
ic/cardiovascular comorbidities
Starting date September 2007
Contact information Bristol Myers Squibb
Notes  
EudraCT2006-00311417  (Continued)
 
 
Trial name or title New-onset diabetes mellitus after renal transplantation. A multicentre, prospective randomized,
open study to evaluate belatacept-based versus tacrolimus-based immunosuppression
Methods Open label RCT
Participants Patients aged either > 60, or > 45 at high risk of glucose metabolism disorder after kidney trans-
plant
Interventions Belatacept versus tacrolimus
Outcomes Primary: incidence of glucose metabolism disorder at 6 months. Secondary: acute rejection, graM
survival and function
Starting date May 2013
Contact information Frances Mateos. Hospital Vall d'Hebron. Department of Nephrology
Notes  
EudraCT2011-00616240 
 
 
Trial name or title Cardiovascular risk prediction and biomarkers in renal transplant recipients treated with belata-
cept compared to calcineurin inhibitors
Methods Open label RCT
Participants Adult recipients of living or deceased-donor kidney transplants
Interventions Belatacept versus CNI
Outcomes Primary: cardiovascular risk calculated by risk calculator in transplant recipients
Secondary: blood pressure, lipids, glucose, graM function
Starting date October 2013
Contact information Elin Karlberg, Uppsala University Hospital, Sweden
EudraCT2013-00117820 
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Notes  
EudraCT2013-00117820  (Continued)
 
 
Trial name or title Belatacept early steroid withdrawal trial
Methods Open label RCT
Participants 315, > 18 y, recipient of living or deceased-donor kidney transplant
Interventions Belatacept versus tacrolimus, both with early steroid withdrawal and either alemtuzumab or ATG
induction
Outcomes Primary: composite patient death or graM loss of eGFR < 45
Starting date September 2012
Contact information E. Steve Woddle, University of Cincinnati, USA
Notes  
NCT01729494 
 
 
Trial name or title Belatacept study (BMS no. 55230)
Methods Open label, unblinded RCT
Participants 40
Interventions Belatacept versus tacrolimus
Outcomes Primary: CD4+ and CD8+ cell counts
Secondary: incidence acute rejection, eGFR (MDRD), infections, malignancy, PTLD
Starting date October 2013
Contact information DA Hesselink, Erasmus Medical Centre, Rotterdam, The Netherlands
Notes  
NTR4242 
ATG - antithymocyte globulin; CNI - calcineurin inhibitor; eGFR - estimated glomerular filtration rate; MDRD - Modification of Diet in Renal
Disease; MMF - mycophenolate mofetil; PTLD - post-transplant lymphoproliferative disorder; RCT - randomised controlled trial
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Comparison 1.   Any dosage belatacept versus calcineurin inhibitor (CNI)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recipient and kidney survival 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death (any cause) 4 1516 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.39, 1.44]
1.2 Loss of kidney transplant 4 1516 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.61, 1.38]
2 Surviving with a functioning trans-
plant
4 1516 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.96, 1.06]
3 Acute rejection and chronic kidney
scarring
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Acute rejection 4 1516 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.85, 2.86]
3.2 Severe acute rejection (≥ BanG 2A) 3 200 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.76, 1.37]
3.3 Chronic kidney scarring 3 1360 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.55, 0.94]
3.4 Severe chronic kidney scarring 3 1360 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.42, 1.32]
4 Kidney function, blood pressure and
lipids
4   Mean Difference (IV, Random,
95% CI)
Subtotals only
4.1 Measured GFR 3 1083 Mean Difference (IV, Random,
95% CI)
10.89 [4.01, 17.77]
4.2 eGFR 4 1133 Mean Difference (IV, Random,
95% CI)
9.96 [3.28, 16.64]
4.3 Systolic BP 2 658 Mean Difference (IV, Random,
95% CI)
-7.51 [-10.57, -4.46]
4.4 Diastolic BP 2 658 Mean Difference (IV, Random,
95% CI)
-3.07 [-4.83, -1.31]
4.5 non-HDL (change from baseline) 3 1101 Mean Difference (IV, Random,
95% CI)
-12.25 [-17.93, -6.57]
4.6 Triglycerides (change from baseline) 3 1101 Mean Difference (IV, Random,
95% CI)
-24.09 [-44.55, -3.64]
5 Malignancy 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Any malignancy 4 1516 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.58, 1.72]
5.2 PTLD 4 1516 Risk Ratio (M-H, Random, 95% CI) 2.79 [0.61, 12.66]
6 Infections 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Any infection 4 1516 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.87, 1.09]
6.2 Serious infection 2 1209 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.83, 1.12]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6.3 Tuberculosis 2 1209 Risk Ratio (M-H, Random, 95% CI) 3.96 [0.72, 21.67]
6.4 CMV disease 2 1209 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.91, 2.50]
6.5 BK nephropathy 1 666 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.05, 1.35]
7 Diabetes and use of blood pressure
medicines
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 New-onset diabetes 4 1049 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.40, 0.93]
7.2 1 or 2 blood pressure medicines 2 755 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.67, 0.92]
7.3 3 or more blood pressure medicines 3 1298 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.65, 1.07]
 
 
Analysis 1.1.   Comparison 1 Any dosage belatacept versus
calcineurin inhibitor (CNI), Outcome 1 Recipient and kidney survival.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Death (any cause)  
Ferguson 2010 1/59 0/30 3.92% 1.55[0.07,36.94]
Vincenti 2005 1/145 4/73 7.85% 0.13[0.01,1.11]
BENEFIT Study 2008 19/445 15/221 41% 0.63[0.33,1.21]
BENEFIT-EXT 2009 37/359 17/184 47.23% 1.12[0.65,1.93]
Subtotal (95% CI) 1008 508 100% 0.75[0.39,1.44]
Total events: 58 (Belatacept), 36 (CNI)  
Heterogeneity: Tau2=0.15; Chi2=4.87, df=3(P=0.18); I2=38.34%  
Test for overall effect: Z=0.86(P=0.39)  
   
1.1.2 Loss of kidney transplant  
Ferguson 2010 4/59 0/30 2.04% 4.65[0.26,83.62]
Vincenti 2005 4/145 2/73 6.08% 1.01[0.19,5.37]
BENEFIT Study 2008 19/445 10/221 30.39% 0.94[0.45,1.99]
BENEFIT-EXT 2009 33/359 20/184 61.49% 0.85[0.5,1.43]
Subtotal (95% CI) 1008 508 100% 0.91[0.61,1.38]
Total events: 60 (Belatacept), 32 (CNI)  
Heterogeneity: Tau2=0; Chi2=1.34, df=3(P=0.72); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
Test for subgroup differences: Chi2=0.25, df=1 (P=0.62), I2=0%  
More common: CNI 1000.01 100.1 1 More common: belatacept
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Analysis 1.2.   Comparison 1 Any dosage belatacept versus calcineurin
inhibitor (CNI), Outcome 2 Surviving with a functioning transplant.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
BENEFIT Study 2008 407/445 197/221 34.87% 1.03[0.97,1.08]
BENEFIT-EXT 2009 291/359 147/184 20.63% 1.01[0.93,1.11]
Ferguson 2010 54/59 30/30 19.42% 0.92[0.84,1.01]
Vincenti 2005 140/145 67/73 25.08% 1.05[0.98,1.13]
   
Total (95% CI) 1008 508 100% 1.01[0.96,1.06]
Total events: 892 (Belatacept), 441 (CNI)  
Heterogeneity: Tau2=0; Chi2=5.17, df=3(P=0.16); I2=41.99%  
Test for overall effect: Z=0.36(P=0.72)  
More common: CNI 1 More common: belatacept
 
 
Analysis 1.3.   Comparison 1 Any dosage belatacept versus calcineurin
inhibitor (CNI), Outcome 3 Acute rejection and chronic kidney scarring.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Acute rejection  
Ferguson 2010 5/59 1/30 7.02% 2.54[0.31,20.79]
Vincenti 2005 9/145 6/73 20.52% 0.76[0.28,2.04]
BENEFIT Study 2008 88/445 16/221 34.77% 2.73[1.64,4.54]
BENEFIT-EXT 2009 64/359 26/184 37.69% 1.26[0.83,1.92]
Subtotal (95% CI) 1008 508 100% 1.56[0.85,2.86]
Total events: 166 (Belatacept), 49 (CNI)  
Heterogeneity: Tau2=0.21; Chi2=8.02, df=3(P=0.05); I2=62.57%  
Test for overall effect: Z=1.44(P=0.15)  
   
1.3.2 Severe acute rejection (≥ Ban: 2A)  
Ferguson 2010 0/5 0/1   Not estimable
BENEFIT Study 2008 56/88 8/16 25.95% 1.27[0.76,2.13]
BENEFIT-EXT 2009 51/64 22/26 74.05% 0.94[0.77,1.16]
Subtotal (95% CI) 157 43 100% 1.02[0.76,1.37]
Total events: 107 (Belatacept), 30 (CNI)  
Heterogeneity: Tau2=0.02; Chi2=1.51, df=1(P=0.22); I2=33.71%  
Test for overall effect: Z=0.12(P=0.91)  
   
1.3.3 Chronic kidney scarring  
Vincenti 2005 26/106 20/45 20.29% 0.55[0.35,0.88]
BENEFIT Study 2008 94/445 71/221 35.77% 0.66[0.51,0.85]
BENEFIT-EXT 2009 162/359 95/184 43.94% 0.87[0.73,1.05]
Subtotal (95% CI) 910 450 100% 0.72[0.55,0.94]
Total events: 282 (Belatacept), 186 (CNI)  
Heterogeneity: Tau2=0.03; Chi2=5.32, df=2(P=0.07); I2=62.41%  
Test for overall effect: Z=2.44(P=0.01)  
   
1.3.4 Severe chronic kidney scarring  
Vincenti 2005 4/106 1/45 7% 1.7[0.2,14.77]
BENEFIT Study 2008 10/445 6/221 32.83% 0.83[0.3,2.25]
More common: CNI 1000.01 100.1 1 More common: belatacept
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Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
BENEFIT-EXT 2009 15/359 12/184 60.17% 0.64[0.31,1.34]
Subtotal (95% CI) 910 450 100% 0.75[0.42,1.32]
Total events: 29 (Belatacept), 19 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.76, df=2(P=0.68); I2=0%  
Test for overall effect: Z=1(P=0.32)  
Test for subgroup differences: Chi2=6.92, df=1 (P=0.07), I2=56.63%  
More common: CNI 1000.01 100.1 1 More common: belatacept
 
 
Analysis 1.4.   Comparison 1 Any dosage belatacept versus calcineurin
inhibitor (CNI), Outcome 4 Kidney function, blood pressure and lipids.
Study or subgroup Belatacept CNI Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.4.1 Measured GFR  
Vincenti 2005 69 64.1 (18.3) 27 53.5 (16.4) 28.37% 10.55[3.01,18.09]
BENEFIT-EXT 2009 275 50.6 (23) 136 45 (27.2) 34.26% 5.6[0.28,10.92]
BENEFIT Study 2008 391 66.5 (28.6) 185 50.5 (20.5) 37.37% 16[11.91,20.09]
Subtotal *** 735   348   100% 10.89[4.01,17.77]
Heterogeneity: Tau2=28.57; Chi2=9.37, df=2(P=0.01); I2=78.66%  
Test for overall effect: Z=3.1(P=0)  
   
1.4.2 eGFR  
Vincenti 2005 102 75.8 (20.1) 23 74.4 (23.7) 18.62% 1.4[-9.04,11.84]
Ferguson 2010 59 63 (29) 30 54 (15) 20.84% 9[-0.14,18.14]
BENEFIT-EXT 2009 258 43.5 (25.4) 127 35 (21.6) 28.94% 8.48[3.61,13.35]
BENEFIT Study 2008 370 70 (19.2) 164 53 (17.1) 31.6% 17[13.73,20.27]
Subtotal *** 789   344   100% 9.96[3.28,16.64]
Heterogeneity: Tau2=33.95; Chi2=14.52, df=3(P=0); I2=79.34%  
Test for overall effect: Z=2.92(P=0)  
   
1.4.3 Systolic BP  
Ferguson 2010 59 128 (13.8) 30 138.3 (19.5) 15.28% -10.3[-18.12,-2.48]
BENEFIT Study 2008 383 132 (16.4) 186 139 (20.1) 84.72% -7.01[-10.33,-3.69]
Subtotal *** 442   216   100% -7.51[-10.57,-4.46]
Heterogeneity: Tau2=0; Chi2=0.58, df=1(P=0.45); I2=0%  
Test for overall effect: Z=4.82(P<0.0001)  
   
1.4.4 Diastolic BP  
Ferguson 2010 59 74.1 (11.4) 30 77.6 (10.5) 13.65% -3.51[-8.26,1.24]
BENEFIT Study 2008 383 79 (9.9) 186 82 (11.2) 86.35% -3[-4.89,-1.11]
Subtotal *** 442   216   100% -3.07[-4.83,-1.31]
Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.85); I2=0%  
Test for overall effect: Z=3.42(P=0)  
   
1.4.5 non-HDL (change from baseline)  
Ferguson 2010 59 16 (44.9) 30 20.5 (42.6) 8.59% -4.46[-23.52,14.6]
BENEFIT-EXT 2009 359 11.9 (48.2) 184 29.3 (51.5) 34.99% -17.38[-26.33,-8.43]
BENEFIT Study 2008 312 8 (34.9) 157 18.3 (35.1) 56.42% -10.26[-16.98,-3.54]
Subtotal *** 730   371   100% -12.25[-17.93,-6.57]
Higher with CNI 10050-100 -50 0 Higher with belatacept
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Study or subgroup Belatacept CNI Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=3.13; Chi2=2.24, df=2(P=0.33); I2=10.66%  
Test for overall effect: Z=4.23(P<0.0001)  
   
1.4.6 Triglycerides (change from baseline)  
BENEFIT-EXT 2009 359 -9.4 (125.6) 184 34.5 (135.6) 29.66% -43.9[-67.41,-20.39]
Ferguson 2010 59 15.3 (44.2) 30 20 (45.8) 33.37% -4.7[-24.59,15.19]
BENEFIT Study 2008 312 -19.1 (86.6) 157 6.6 (86) 36.98% -25.71[-42.24,-9.18]
Subtotal *** 730   371   100% -24.09[-44.55,-3.64]
Heterogeneity: Tau2=223.48; Chi2=6.39, df=2(P=0.04); I2=68.7%  
Test for overall effect: Z=2.31(P=0.02)  
Test for subgroup differences: Chi2=52.3, df=1 (P<0.0001), I2=90.44%  
Higher with CNI 10050-100 -50 0 Higher with belatacept
 
 
Analysis 1.5.   Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 5 Malignancy.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Any malignancy  
Ferguson 2010 1/59 1/30 3.93% 0.51[0.03,7.85]
Vincenti 2005 2/145 2/73 7.83% 0.5[0.07,3.5]
BENEFIT-EXT 2009 7/359 4/184 19.94% 0.9[0.27,3.02]
BENEFIT Study 2008 28/445 12/221 68.3% 1.16[0.6,2.23]
Subtotal (95% CI) 1008 508 100% 1[0.58,1.72]
Total events: 38 (Belatacept), 19 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.94, df=3(P=0.82); I2=0%  
Test for overall effect: Z=0(P=1)  
   
1.5.2 PTLD  
Ferguson 2010 0/59 0/30   Not estimable
Vincenti 2005 1/145 0/73 22.55% 1.52[0.06,36.87]
BENEFIT-EXT 2009 5/359 0/184 27.45% 5.65[0.31,101.67]
BENEFIT Study 2008 5/445 1/221 50% 2.48[0.29,21.13]
Subtotal (95% CI) 1008 508 100% 2.79[0.61,12.66]
Total events: 11 (Belatacept), 1 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.39, df=2(P=0.82); I2=0%  
Test for overall effect: Z=1.33(P=0.18)  
Test for subgroup differences: Chi2=1.56, df=1 (P=0.21), I2=36.05%  
More common: CNI 2000.005 100.1 1 More common: belatacept
 
 
Analysis 1.6.   Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 6 Infections.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 Any infection  
Ferguson 2010 46/59 20/30 11.99% 1.17[0.88,1.56]
BENEFIT-EXT 2009 148/359 92/184 21.21% 0.82[0.68,1]
Vincenti 2005 106/145 55/73 25.02% 0.97[0.82,1.14]
More common: CNI 2000.005 100.1 1 More common: belatacept
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Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
BENEFIT Study 2008 360/445 176/221 41.78% 1.02[0.94,1.1]
Subtotal (95% CI) 1008 508 100% 0.98[0.87,1.09]
Total events: 660 (Belatacept), 343 (CNI)  
Heterogeneity: Tau2=0.01; Chi2=5.85, df=3(P=0.12); I2=48.72%  
Test for overall effect: Z=0.4(P=0.69)  
   
1.6.2 Serious infection  
BENEFIT Study 2008 134/445 69/221 40.27% 0.96[0.76,1.23]
BENEFIT-EXT 2009 156/359 83/184 59.73% 0.96[0.79,1.17]
Subtotal (95% CI) 804 405 100% 0.96[0.83,1.12]
Total events: 290 (Belatacept), 152 (CNI)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.47(P=0.64)  
   
1.6.3 Tuberculosis  
BENEFIT-EXT 2009 6/359 0/184 35.09% 6.68[0.38,117.94]
BENEFIT Study 2008 6/445 1/221 64.91% 2.98[0.36,24.6]
Subtotal (95% CI) 804 405 100% 3.96[0.72,21.67]
Total events: 12 (Belatacept), 1 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=1.58(P=0.11)  
   
1.6.4 CMV disease  
BENEFIT Study 2008 24/445 7/221 37.23% 1.7[0.75,3.89]
BENEFIT-EXT 2009 33/359 12/184 62.77% 1.41[0.75,2.66]
Subtotal (95% CI) 804 405 100% 1.51[0.91,2.5]
Total events: 57 (Belatacept), 19 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=1.61(P=0.11)  
   
1.6.5 BK nephropathy  
BENEFIT Study 2008 2/445 4/221 100% 0.25[0.05,1.35]
Subtotal (95% CI) 445 221 100% 0.25[0.05,1.35]
Total events: 2 (Belatacept), 4 (CNI)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.11)  
Test for subgroup differences: Chi2=8, df=1 (P=0.09), I2=49.97%  
More common: CNI 2000.005 100.1 1 More common: belatacept
 
 
Analysis 1.7.   Comparison 1 Any dosage belatacept versus calcineurin
inhibitor (CNI), Outcome 7 Diabetes and use of blood pressure medicines.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.7.1 New-onset diabetes  
Ferguson 2010 2/41 1/17 3.23% 0.83[0.08,8.55]
Vincenti 2005 8/94 2/22 8.04% 0.94[0.21,4.11]
BENEFIT-EXT 2009 14/270 12/119 32.07% 0.51[0.25,1.08]
BENEFIT Study 2008 25/324 20/162 56.66% 0.63[0.36,1.09]
More common: CNI 200.05 50.2 1 More common: belatacept
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Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 729 320 100% 0.61[0.4,0.93]
Total events: 49 (Belatacept), 35 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.6, df=3(P=0.9); I2=0%  
Test for overall effect: Z=2.3(P=0.02)  
   
1.7.2 1 or 2 blood pressure medicines  
Ferguson 2010 30/59 17/30 16.18% 0.9[0.6,1.34]
BENEFIT Study 2008 171/445 111/221 83.82% 0.77[0.64,0.91]
Subtotal (95% CI) 504 251 100% 0.79[0.67,0.92]
Total events: 201 (Belatacept), 128 (CNI)  
Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.48); I2=0%  
Test for overall effect: Z=2.94(P=0)  
   
1.7.3 3 or more blood pressure medicines  
Ferguson 2010 15/59 3/30 4.24% 2.54[0.8,8.1]
BENEFIT Study 2008 132/445 86/221 45.68% 0.76[0.61,0.95]
BENEFIT-EXT 2009 148/359 92/184 50.08% 0.82[0.68,1]
Subtotal (95% CI) 863 435 100% 0.83[0.65,1.07]
Total events: 295 (Belatacept), 181 (CNI)  
Heterogeneity: Tau2=0.02; Chi2=4.11, df=2(P=0.13); I2=51.36%  
Test for overall effect: Z=1.44(P=0.15)  
More common: CNI 200.05 50.2 1 More common: belatacept
 
 
Comparison 2.   High versus low dosage belatacept
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recipient and kidney survival 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death (any cause) 3 949 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.75, 2.06]
1.2 Loss of kidney transplant 3 949 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.59, 1.56]
2 Surviving with a functioning trans-
plant
3 949 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.94, 1.02]
3 Acute rejection and chronic kidney
scarring
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Acute rejection 3 949 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.88, 1.55]
3.2 Severe acute rejection (≥ BanG 2A) 2 152 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.67, 2.43]
3.3 Chronic kidney scarring 3 910 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.74, 1.20]
3.4 Severe chronic kidney scarring 3 910 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.34, 1.75]
4 Kidney function, blood pressure and
lipids
3   Mean Difference (IV, Random,
95% CI)
Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.1 Measured GFR 3 735 Mean Difference (IV, Random,
95% CI)
0.37 [-3.49, 4.23]
4.2 eGFR 3 747 Mean Difference (IV, Random,
95% CI)
0.13 [-2.94, 3.20]
4.3 Systolic BP 2 659 Mean Difference (IV, Random,
95% CI)
1.16 [-1.33, 3.66]
4.4 Diastolic BP 2 659 Mean Difference (IV, Random,
95% CI)
0.0 [-1.52, 1.52]
4.5 non-HDL (change from baseline) 2 671 Mean Difference (IV, Random,
95% CI)
0.59 [-5.54, 6.72]
4.6 Triglycerides (change from baseline) 2 671 Mean Difference (IV, Random,
95% CI)
8.82 [-6.63, 24.28]
5 Malignancy 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Any malignancy 3 949 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.52, 3.13]
5.2 PTLD 3 949 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.39, 3.99]
6 Infections 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Any infection 3 949 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.04]
6.2 Serious infection 2 804 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.73, 1.09]
6.3 Tuberculosis 2 804 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.23, 4.17]
6.4 CMV disease 3 949 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.74, 1.40]
6.5 BK nephropathy 1 445 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.06, 16.40]
7 Diabetes and use of blood pressure
medicines
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 New-onset diabetes 3 739 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.33, 2.51]
7.2 1 or 2 blood pressure medicines 1 445 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.91, 1.45]
7.3 3 or more blood pressure medicines 2 804 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.91, 1.32]
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Analysis 2.1.   Comparison 2 High versus low dosage belatacept, Outcome 1 Recipient and kidney survival.
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 Death (any cause)  
Vincenti 2005 1/74 0/71 2.49% 2.88[0.12,69.55]
BENEFIT Study 2008 9/219 10/226 32.49% 0.93[0.38,2.24]
BENEFIT-EXT 2009 22/184 15/175 65.03% 1.39[0.75,2.6]
Subtotal (95% CI) 477 472 100% 1.24[0.75,2.06]
Total events: 32 (High dosage belatacept), 25 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=0.82, df=2(P=0.66); I2=0%  
Test for overall effect: Z=0.85(P=0.39)  
   
2.1.2 Loss of kidney transplant  
Vincenti 2005 3/74 1/71 4.8% 2.88[0.31,27.03]
BENEFIT Study 2008 10/219 9/226 31.02% 1.15[0.48,2.77]
BENEFIT-EXT 2009 17/184 20/175 64.18% 0.81[0.44,1.49]
Subtotal (95% CI) 477 472 100% 0.96[0.59,1.56]
Total events: 30 (High dosage belatacept), 30 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%  
Test for overall effect: Z=0.17(P=0.86)  
Test for subgroup differences: Chi2=0.54, df=1 (P=0.46), I2=0%  
More common: high dosage 1000.01 100.1 1 More common: low dosage
 
 
Analysis 2.2.   Comparison 2 High versus low dosage belatacept, Outcome 2 Surviving with a functioning transplant.
Study or subgroup Belatacept CNI Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
BENEFIT Study 2008 202/219 208/226 48.12% 1[0.95,1.06]
BENEFIT-EXT 2009 145/184 145/175 13.96% 0.95[0.86,1.05]
Vincenti 2005 70/74 70/71 37.92% 0.96[0.9,1.02]
   
Total (95% CI) 477 472 100% 0.98[0.94,1.02]
Total events: 417 (Belatacept), 423 (CNI)  
Heterogeneity: Tau2=0; Chi2=1.45, df=2(P=0.48); I2=0%  
Test for overall effect: Z=1.13(P=0.26)  
More common: CNI 1 More common: belatacept
 
 
Analysis 2.3.   Comparison 2 High versus low dosage belatacept,
Outcome 3 Acute rejection and chronic kidney scarring.
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Acute rejection  
Vincenti 2005 5/74 4/71 4.85% 1.2[0.34,4.29]
BENEFIT-EXT 2009 33/184 31/175 39.86% 1.01[0.65,1.58]
BENEFIT Study 2008 49/219 39/226 55.29% 1.3[0.89,1.89]
Subtotal (95% CI) 477 472 100% 1.17[0.88,1.55]
More common: high dosage 2000.005 100.1 1 More common: low dosage
Belatacept for kidney transplant recipients (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
47
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 87 (High dosage belatacept), 74 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=0.69, df=2(P=0.71); I2=0%  
Test for overall effect: Z=1.1(P=0.27)  
   
2.3.2 Severe acute rejection (≥ Ban: 2A)  
BENEFIT Study 2008 37/49 17/39 46.89% 1.73[1.17,2.56]
BENEFIT-EXT 2009 27/33 26/31 53.11% 0.98[0.78,1.22]
Subtotal (95% CI) 82 70 100% 1.28[0.67,2.43]
Total events: 64 (High dosage belatacept), 43 (Low dosage belatacept)  
Heterogeneity: Tau2=0.19; Chi2=8.19, df=1(P=0); I2=87.79%  
Test for overall effect: Z=0.75(P=0.46)  
   
2.3.3 Chronic kidney scarring  
Vincenti 2005 15/52 11/54 11.59% 1.42[0.72,2.79]
BENEFIT Study 2008 40/219 54/226 31.99% 0.76[0.53,1.1]
BENEFIT-EXT 2009 82/184 80/175 56.43% 0.97[0.78,1.22]
Subtotal (95% CI) 455 455 100% 0.94[0.74,1.2]
Total events: 137 (High dosage belatacept), 145 (Low dosage belatacept)  
Heterogeneity: Tau2=0.01; Chi2=2.75, df=2(P=0.25); I2=27.28%  
Test for overall effect: Z=0.48(P=0.63)  
   
2.3.4 Severe chronic kidney scarring  
Vincenti 2005 0/52 4/54 7.79% 0.12[0.01,2.09]
BENEFIT Study 2008 4/219 6/226 37.28% 0.69[0.2,2.4]
BENEFIT-EXT 2009 8/184 7/175 54.93% 1.09[0.4,2.93]
Subtotal (95% CI) 455 455 100% 0.77[0.34,1.75]
Total events: 12 (High dosage belatacept), 17 (Low dosage belatacept)  
Heterogeneity: Tau2=0.06; Chi2=2.23, df=2(P=0.33); I2=10.21%  
Test for overall effect: Z=0.63(P=0.53)  
Test for subgroup differences: Chi2=2.22, df=1 (P=0.53), I2=0%  
More common: high dosage 2000.005 100.1 1 More common: low dosage
 
 
Analysis 2.4.   Comparison 2 High versus low dosage belatacept,
Outcome 4 Kidney function, blood pressure and lipids.
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 Measured GFR  
Vincenti 2005 32 66.3 (20.7) 37 62.1 (15.9) 17.89% 4.2[-4.61,13.01]
BENEFIT Study 2008 192 65 (27.2) 199 67.9 (29.9) 39.55% -2.9[-8.56,2.76]
BENEFIT-EXT 2009 136 51.5 (22.2) 139 49.7 (23.7) 42.56% 1.8[-3.62,7.22]
Subtotal *** 360   375   100% 0.37[-3.49,4.23]
Heterogeneity: Tau2=1.46; Chi2=2.27, df=2(P=0.32); I2=12.01%  
Test for overall effect: Z=0.19(P=0.85)  
   
2.4.2 eGFR  
Vincenti 2005 60 72.4 (22.5) 59 73.2 (22.5) 14.41% -0.8[-8.89,7.29]
BENEFIT-EXT 2009 125 44 (26.7) 133 43 (24.1) 24.36% 1[-5.22,7.22]
Favours low dosage 5025-50 -25 0 Favours high dosage
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Study or subgroup High dosage
belatacept
Low dosage
belatacept
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
BENEFIT Study 2008 180 70 (18.8) 190 70 (19.7) 61.23% 0[-3.92,3.92]
Subtotal *** 365   382   100% 0.13[-2.94,3.2]
Heterogeneity: Tau2=0; Chi2=0.13, df=2(P=0.94); I2=0%  
Test for overall effect: Z=0.08(P=0.93)  
   
2.4.3 Systolic BP  
BENEFIT-EXT 2009 137 141 (16.2) 139 141 (16.5) 41.88% 0[-3.86,3.86]
BENEFIT Study 2008 190 133 (16.2) 193 131 (16.5) 58.12% 2[-1.27,5.27]
Subtotal *** 327   332   100% 1.16[-1.33,3.66]
Heterogeneity: Tau2=0; Chi2=0.6, df=1(P=0.44); I2=0%  
Test for overall effect: Z=0.91(P=0.36)  
   
2.4.4 Diastolic BP  
BENEFIT-EXT 2009 137 78 (11.6) 139 78 (7.9) 41.89% 0[-2.34,2.34]
BENEFIT Study 2008 190 79 (11.6) 193 79 (7.9) 58.11% 0[-1.99,1.99]
Subtotal *** 327   332   100% 0[-1.52,1.52]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%  
Test for overall effect: Not applicable  
   
2.4.5 non-HDL (change from baseline)  
BENEFIT-EXT 2009 184 12.6 (48.8) 175 11.2 (47.6) 37.76% 1.4[-8.57,11.37]
BENEFIT Study 2008 155 8.1 (34.9) 157 8 (35.1) 62.24% 0.1[-7.67,7.87]
Subtotal *** 339   332   100% 0.59[-5.54,6.72]
Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.84); I2=0%  
Test for overall effect: Z=0.19(P=0.85)  
   
2.4.6 Triglycerides (change from baseline)  
BENEFIT-EXT 2009 184 -1 (128.9) 175 -18.2
(121.7)
35.55% 17.2[-8.72,43.12]
BENEFIT Study 2008 155 -17 (87) 157 -21.2 (86.5) 64.45% 4.2[-15.05,23.45]
Subtotal *** 339   332   100% 8.82[-6.63,24.28]
Heterogeneity: Tau2=0; Chi2=0.62, df=1(P=0.43); I2=0%  
Test for overall effect: Z=1.12(P=0.26)  
Test for subgroup differences: Chi2=1.79, df=1 (P=0.88), I2=0%  
Favours low dosage 5025-50 -25 0 Favours high dosage
 
 
Analysis 2.5.   Comparison 2 High versus low dosage belatacept, Outcome 5 Malignancy.
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Any malignancy  
Vincenti 2005 2/74 0/71 8.9% 4.8[0.23,98.27]
BENEFIT-EXT 2009 4/184 4/175 43.21% 0.95[0.24,3.74]
BENEFIT Study 2008 5/219 4/226 47.89% 1.29[0.35,4.74]
Subtotal (95% CI) 477 472 100% 1.27[0.52,3.13]
Total events: 11 (High dosage belatacept), 8 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=0.93, df=2(P=0.63); I2=0%  
Test for overall effect: Z=0.52(P=0.6)  
More common: low dosage 1000.01 100.1 1 More common: high dosage
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Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
2.5.2 PTLD  
Vincenti 2005 2/74 0/71 14.78% 4.8[0.23,98.27]
BENEFIT Study 2008 3/219 2/226 42.55% 1.55[0.26,9.17]
BENEFIT-EXT 2009 2/184 3/175 42.66% 0.63[0.11,3.75]
Subtotal (95% CI) 477 472 100% 1.25[0.39,3.99]
Total events: 7 (High dosage belatacept), 5 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=1.39, df=2(P=0.5); I2=0%  
Test for overall effect: Z=0.38(P=0.71)  
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%  
More common: low dosage 1000.01 100.1 1 More common: high dosage
 
 
Analysis 2.6.   Comparison 2 High versus low dosage belatacept, Outcome 6 Infections.
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.6.1 Any infection  
Vincenti 2005 54/74 52/71 10.33% 1[0.82,1.21]
BENEFIT-EXT 2009 147/184 144/175 40.38% 0.97[0.88,1.07]
BENEFIT Study 2008 175/219 185/226 49.28% 0.98[0.89,1.07]
Subtotal (95% CI) 477 472 100% 0.98[0.92,1.04]
Total events: 376 (High dosage belatacept), 381 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=0.05, df=2(P=0.97); I2=0%  
Test for overall effect: Z=0.75(P=0.46)  
   
2.6.2 Serious infection  
BENEFIT Study 2008 66/219 68/226 42.74% 1[0.75,1.33]
BENEFIT-EXT 2009 72/184 84/175 57.26% 0.82[0.64,1.03]
Subtotal (95% CI) 403 401 100% 0.89[0.73,1.09]
Total events: 138 (High dosage belatacept), 152 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=1.21, df=1(P=0.27); I2=17.12%  
Test for overall effect: Z=1.14(P=0.26)  
   
2.6.3 Tuberculosis  
BENEFIT Study 2008 4/219 2/226 49.95% 2.06[0.38,11.15]
BENEFIT-EXT 2009 2/184 4/175 50.05% 0.48[0.09,2.56]
Subtotal (95% CI) 403 401 100% 0.99[0.23,4.17]
Total events: 6 (High dosage belatacept), 6 (Low dosage belatacept)  
Heterogeneity: Tau2=0.34; Chi2=1.46, df=1(P=0.23); I2=31.32%  
Test for overall effect: Z=0.01(P=0.99)  
   
2.6.4 CMV disease  
Vincenti 2005 11/74 10/71 16.56% 1.06[0.48,2.33]
BENEFIT Study 2008 22/219 26/226 36.1% 0.87[0.51,1.49]
BENEFIT-EXT 2009 32/184 27/175 47.34% 1.13[0.71,1.8]
Subtotal (95% CI) 477 472 100% 1.02[0.74,1.4]
Total events: 65 (High dosage belatacept), 63 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=0.5, df=2(P=0.78); I2=0%  
More common: high dosage 200.05 50.2 1 More common: low dosage
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Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.1(P=0.92)  
   
2.6.5 BK nephropathy  
BENEFIT Study 2008 1/219 1/226 100% 1.03[0.06,16.4]
Subtotal (95% CI) 219 226 100% 1.03[0.06,16.4]
Total events: 1 (High dosage belatacept), 1 (Low dosage belatacept)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
Test for subgroup differences: Chi2=0.82, df=1 (P=0.94), I2=0%  
More common: high dosage 200.05 50.2 1 More common: low dosage
 
 
Analysis 2.7.   Comparison 2 High versus low dosage belatacept,
Outcome 7 Diabetes and use of blood pressure medicines.
Study or subgroup High dosage
belatacept
Low dosage
belatacept
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.7.1 New-onset diabetes  
Vincenti 2005 1/74 1/71 11.49% 0.96[0.06,15.05]
BENEFIT-EXT 2009 4/133 10/137 37.84% 0.41[0.13,1.28]
BENEFIT Study 2008 15/156 10/168 50.68% 1.62[0.75,3.49]
Subtotal (95% CI) 363 376 100% 0.91[0.33,2.51]
Total events: 20 (High dosage belatacept), 21 (Low dosage belatacept)  
Heterogeneity: Tau2=0.38; Chi2=3.83, df=2(P=0.15); I2=47.82%  
Test for overall effect: Z=0.19(P=0.85)  
   
2.7.2 1 or 2 blood pressure medicines  
BENEFIT Study 2008 90/219 81/226 100% 1.15[0.91,1.45]
Subtotal (95% CI) 219 226 100% 1.15[0.91,1.45]
Total events: 90 (High dosage belatacept), 81 (Low dosage belatacept)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.26)  
   
2.7.3 3 or more blood pressure medicines  
BENEFIT Study 2008 66/219 66/226 43.07% 1.03[0.78,1.37]
BENEFIT-EXT 2009 81/184 67/175 56.93% 1.15[0.9,1.47]
Subtotal (95% CI) 403 401 100% 1.1[0.91,1.32]
Total events: 147 (High dosage belatacept), 133 (Low dosage belatacept)  
Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.57); I2=0%  
Test for overall effect: Z=0.97(P=0.33)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.89), I2=0%  
More common: low dosage 200.05 50.2 1 More common: high dosage
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Database Search terms
CENTRAL 1. MeSH descriptor Kidney Transplantation, this term only
2. (kidney transplant*):ti,ab,kw in Clinical Trials
3. (#1 OR #2)
4. (Belatacept):ti,ab,kw in Clinical Trials
5. (lea29y):ti,ab,kw in Clinical Trials
6. (bms 224818):ti,ab,kw in Clinical Trials
7. (costimulation blocker*):ti,ab,kw or (co-stimulation blocker*):ti,ab,kw in Clinical Trials
8. (#4 OR #5 OR #6 OR #7)
9. (#3 AND #8)
MEDLINE (OVID SP) 1. Kidney Transplantation/
2. Belatacept.tw.
3. lea29y.tw.
4. "bms 224818".tw.
5. (costimulation blocker$ or co-stimulation blocker$).tw.
6. or/2-5
7. and/1,6
EMBASE (OVID SP) 1. exp kidney transplantation/
2. belatacept/
3. Belatacept.tw.
4. lea 29y.tw.
5. lea29y.tw.
6. bms 224818.tw.
7. (costimulation blocker$ or co-stimulation blocker$).tw.
8. or/2-7
9. and/1,8
 
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
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High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Unclear: Randomisation stated but no information on method used is available.
Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
Selective reporting
Reporting bias due to selective
outcome reporting
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
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not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study appears to be free of other sources of bias.
High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
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